Please login to read the full article.
Scrip Regulatory Affairs
US FDA explains how drug, device companies should deal with off-label use comments on social media sites
28 December 2011
Vibha Sharma
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- US FDA's Rx-to-OTC 'paradigm': Is a smart phone as smart as a doctor?
- Long-awaited EU medtech e-IFU regulation is published, application deferred for one year
- CoE explains benefits of newly-launched eTACT EU drugs anti-counterfeit system
- US PDUFA V deal adds 60-day cushion for new drug, biologic reviews
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
